Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 1 of 1559
`PageID #: 35148
`
`DOCKET # 19
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 2 of 1559
`PageID #: 35149
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`GENENTECH, INC. and CITY OF HOPE,
`
`Plaintiffs and Counterclaims
`Defendants,
`
`Case No. 18-00924-GMS
`
`v.
`
`AMGEN INC.,
`
`CONFIDENTIAL – FILED UNDER
`SEAL PURSUANT TO L.R. 26.2
`
`Defendant and Counterclaim
`Plaintiff.
`
`AMGEN INC.’S ANSWER, AFFIRMATIVE DEFENSES, AND COUNTERCLAIMS
`
`Defendant Amgen Inc. (“Amgen”), by and through its undersigned attorneys, hereby
`
`submits its Answer, Affirmative Defenses, and Counterclaims to the First Amended Complaint for
`
`declaratory and injunctive relief (“Complaint”), filed by Plaintiffs Genentech, Inc. (“Genentech”)
`
`and City of Hope (“City of Hope,” collectively, “Plaintiffs”) on July 19, 2018.
`
`Pursuant to Fed. R. Civ. P. 8(b)(3), Amgen denies each and every allegation in the
`
`Complaint, whether express or implied, except those specifically and expressly admitted below.
`
`Any factual allegation admitted below is admitted only as to the specific admitted facts, not as to
`
`any purported conclusions, characterizations, implications, or speculations that may arguably
`
`follow from the admitted facts. To the extent any allegation in the Complaint is vague and/or
`
`ambiguous, Amgen denies such allegations. Amgen denies that Plaintiffs are entitled to the relief
`
`requested or any other relief.
`
`The headings and subheadings in Amgen’s Answer are used solely for purposes of
`
`convenience and organization to mirror those appearing in the Complaint; to the extent that any
`
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO L.R. 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 3 of 1559
`PageID #: 35150
`
`headings or other non-numbered statements in the Complaint contain or imply any allegations,
`
`Amgen denies each and every allegation therein. Each of the numbered paragraphs in the Answer
`
`below corresponds to the same-numbered paragraphs in the Complaint.
`
`NATURE OF THE CASE
`
`1.
`
`Amgen admits that breast cancer is a serious disease affecting women in the United
`
`States. Amgen further admits that overexpression of HER2 has been found in about 25% to 30%
`
`of human breast cancers and overexpression correlates with poor prognosis in patients with such
`
`cancers. Amgen lacks sufficient knowledge or information to form a belief as to the truth of the
`
`allegations of paragraph 1, and on that basis denies them.
`
`2.
`
`Amgen lacks sufficient knowledge or information to form a belief as to the truth of
`
`the allegations of paragraph 2, and on that basis denies them.
`
`3.
`
`Amgen admits that Herceptin® (hereinafter “Herceptin”) contains the antibody
`
`trastuzumab. Amgen lacks sufficient knowledge or information to form a belief as to the truth of
`
`the remaining allegations of paragraph 3, and on that basis denies them.
`
`4.
`
`Amgen lacks sufficient knowledge or information to form a belief as to the truth of
`
`the allegations of paragraph 4, and on that basis denies them.
`
`5.
`
`Amgen admits that the FDA initially approved Herceptin in 1998. Amgen lacks
`
`sufficient knowledge or information to form a belief as to the truth of the remaining allegations of
`
`paragraph 5, and on that basis denies them.
`
`6.
`
`Amgen admits that the Patent Office has issued patents relating to trastuzumab.
`
`Amgen lacks sufficient knowledge or information to form a belief as to the truth of the remaining
`
`allegations of paragraph 6, and on that basis denies them.
`
`7.
`
`Amgen admits that pursuant to the Biologics Price Competition and Innovation Act
`
`(“BPCIA”), it is seeking FDA approval of a trastuzumab biosimilar called ABP 980. Amgen
`
`- 2 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 4 of 1559
`PageID #: 35151
`
`further admits that it has included in its application for FDA approval of ABP 980 publicly
`
`available information regarding the FDA’s previous determination that Genentech’s trastuzumab
`
`product is safe, pure, and potent. Amgen also admits that it has submitted to FDA a proposed draft
`
`label that contains the same indications for which Herceptin is also approved. Amgen denies the
`
`remaining allegations of paragraph 7.
`
`8.
`
`Amgen admits that Congress enacted the BPCIA in 2010. Amgen further admits
`
`that it has complied with 42 U.S.C. § 262(l). The remaining allegations of paragraph 8 are legal
`
`conclusions that require no response, and on that basis Amgen denies them.
`
`9.
`
`Amgen admits that Plaintiffs have brought an action alleging patent infringement
`
`seeking relief against Amgen. Amgen denies Plaintiffs are entitled to any such relief, requested
`
`or otherwise. Amgen denies the remaining allegations of paragraph 9.
`
`PARTIES
`
`10.
`
`11.
`
`Upon information and belief, Amgen admits the allegations of paragraph 10.
`
`Upon information and belief, Amgen admits that Genentech was founded in 1976
`
`and that Genentech is the sponsor for a number of products that have received FDA approval.
`
`Amgen lacks sufficient knowledge or information to form a belief as to the truth of the remaining
`
`allegations of paragraph 11, and on that basis denies them.
`
`12.
`
`13.
`
`Upon information and belief, Amgen admits the allegations of paragraph 12.
`
`Upon information and belief, Amgen admits that City of Hope was founded in
`
`1913. Amgen lacks sufficient knowledge or information to form a belief as to the truth of the
`
`remaining allegations of paragraph 13, and on that basis denies them.
`
`14.
`
`15.
`
`Amgen admits the allegations of paragraph 14.
`
`Amgen admits the allegations of paragraph 15.
`
`- 3 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 5 of 1559
`PageID #: 35152
`
`JURISDICTION AND VENUE
`
`16.
`
`The allegations of paragraph 16 are legal conclusions that require no response, and
`
`on that basis Amgen denies them.
`
`17.
`
`Amgen admits that it is incorporated in the State of Delaware. The remaining
`
`allegations of paragraph 17 contain legal conclusions that require no response, and on that basis
`
`Amgen denies them.
`
`18.
`
`Amgen admits that it is incorporated in the State of Delaware. Amgen admits that
`
`it has submitted a Biologics License Application (hereinafter “Amgen’s BLA”) seeking FDA
`
`approval of ABP 980. The remaining allegations of paragraph 18 contain legal conclusions that
`
`require no response, and on that basis Amgen denies them.
`
`THE PARTIES’ EXCHANGES UNDER THE BPCIA
`
`19.
`
`Amgen admits that on July 31, 2017, it announced the submission of Amgen’s BLA
`
`to the FDA for ABP 980, which is being developed as a biosimilar to trastuzumab. Upon
`
`information and belief, Amgen admits that Genentech’s trastuzumab is subject to BLA No.
`
`103792. Amgen denies the remaining allegations of paragraph 19.
`
`20.
`
`21.
`
`Amgen admits the allegations of paragraph 20.
`
`Amgen admits that on October 16, 2017, Amgen provided Genentech a copy of
`
`Amgen’s BLA. Amgen denies the remaining allegations of paragraph 21.
`
`22.
`
`23.
`
`Amgen admits the allegations of paragraph 22.
`
`Amgen admits that on November 20, 2017, Genentech requested specific
`
`information concerning the manufacture of Amgen’s biosimilar product and that Amgen provided
`
`additional manufacturing information to Genentech on December 1, 2017, and December 4, 2017.
`
`Amgen further admits that Genentech responded on December 15, 2017. Amgen denies the
`
`remaining allegations of paragraph 23.
`
`- 4 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 6 of 1559
`PageID #: 35153
`
`24.
`
`25.
`
`Amgen denies the allegations of paragraph 24.
`
`Amgen admits that on December 15, 2017, Amgen received a list of 36 patents
`
`from Genentech purporting to comply with Genentech’s statutory obligations pursuant to 42
`
`U.S.C. § 262(l)(3)(A) (“Genentech’s 3A Statement”). Amgen denies the remaining allegations of
`
`paragraph 25.
`
`26.
`
`27.
`
`Amgen admits the allegations of paragraph 26.
`
`Amgen admits that Genentech responded on December 27, 2017. Amgen denies
`
`the remaining allegations of paragraph 27.
`
`28.
`
`29.
`
`Amgen admits the allegations of paragraph 28.
`
`Amgen admits
`
`that on February 6, 2018, Genentech supplemented
`
`its
`
`§ 262(l)(3)(A) list to include U.S. Patent No. 9,868,760. Amgen denies the remaining allegations
`
`of paragraph 29.
`
`30.
`
`Amgen admits that on February 13, 2018, pursuant to 42 U.S.C. § 262(l)(3)(B),
`
`Amgen provided Genentech with its detailed statement concerning non-infringement and
`
`invalidity of the 36 patents identified in Genentech’s December 15, 2017 disclosure (“Amgen’s
`
`3B Statement”). On March 3, 2018, Amgen supplemented its February 13, 2018 disclosure with
`
`its § 262(l)(3)(B) disclosure for U.S. Patent No. 9,868,760. Genentech’s allegation regarding the
`
`sufficiency of Amgen’s 3B statement contains legal conclusions that require no response, and on
`
`that basis Amgen denies them. Amgen denies the remaining allegations of paragraph 30.
`
`31.
`
`Amgen admits that on
`
` and
`
`Amgen produced additional documents regarding
`
`
`
`
`
` Amgen denies the remaining allegations of paragraph 31.
`
`- 5 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 7 of 1559
`PageID #: 35154
`
`32.
`
`Amgen admits that on April 13, 2018, Amgen received Genentech’s responses to
`
`Amgen’s 3B Statement purporting to comply with Genentech’s statutory obligations pursuant to
`
`42 U.S.C. § 262(l)(3)(C) (“Genentech’s 3C Statement”). Amgen admits that Genentech
`
`maintained that ABP 980 will infringe 18 of the 37 Genentech patents identified in Genentech’s
`
`3A Statement, and that Genentech proposed that all 18 of these patents be included in a first-phase
`
`infringement action. Amgen denies the merits of Genentech’s allegations of infringement. Amgen
`
`denies the remaining allegations of paragraph 32.
`
`33.
`
`Amgen admits that on
`
`additional documents regarding
`
` Amgen provided
`
`
`
` Amgen denies the remaining allegations of paragraph 33.
`
`34.
`
`Amgen admits that after Genentech served its 3C Statement, the parties initiated
`
`negotiations under § 262(l)(4). Amgen further admits that Genentech and Amgen agreed that the
`
`37 patents addressed in Genentech’s 3A Statement shall be the subject of an action for patent
`
`infringement under § 262(l)(6)(A). Amgen denies the merits of Genentech’s allegations of
`
`infringement. Amgen denies the remaining allegations of paragraph 34.
`
`35.
`
`Amgen denies the merits of Genentech’s allegations of infringement. The
`
`remaining allegations of paragraph 35 are legal conclusions that require no response, and on that
`
`basis Amgen denies them.
`
`36.
`
`Amgen admits that on May 15, 2018, Amgen notified Genentech pursuant to 42
`
`U.S.C. § 262(l)(8)(A) that it intends to commence first commercial marketing of ABP 980 in the
`
`United States no earlier than 180 days from May 15, 2018 (i.e., November 11, 2018). Amgen
`
`denies the remaining allegations of paragraph 36.
`
`37.
`
`Amgen admits the allegations of paragraph 37.
`
`- 6 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 8 of 1559
`PageID #: 35155
`
`AMGEN’S BLA PRODUCT
`
`38.
`
`Amgen admits that it has publicly stated that its BLA product is a biosimilar
`
`candidate to trastuzumab. Amgen admits the remaining allegations of paragraph 38.
`
`39.
`
`Amgen admits that Amgen’s BLA for trastuzumab included “information
`
`demonstrating that Amgen’s BLA product and trastuzumab utilize the same mechanism of action
`
`. . . for the condition or conditions of use prescribed, recommended, or suggested in the proposed
`
`labeling” submitted in Amgen’s BLA pursuant to 42 U.S.C. § 262(k)(2)(A)(i)(II). Amgen denies
`
`the remaining allegations of paragraph 39.
`
`40.
`
`The allegations of paragraph 40 are legal conclusions that require no response, and
`
`on that basis Amgen denies them.
`
`GENENTECH’S ASSERTED PATENTS
`
`41.
`
`Amgen admits that the United States Patent and Trademark Office has issued
`
`patents relating to trastuzumab, its manufacture, and its use. Amgen lacks sufficient knowledge
`
`or information to form a belief as to the truth of the remaining allegations of paragraph 41, and on
`
`that basis denies them.
`
`42.
`
`Amgen admits that Genentech has asserted the following patents in this lawsuit:
`
`U.S. Patent No. 6,331,415, U.S. Patent No. 7,923,221, U.S. Patent No. 6,407,213, U.S. Patent No.
`
`7,846,441, U.S. Patent No. 7,892,549, U.S. Patent No. 6,627,196, U.S. Patent No. 7,371,379, U.S.
`
`Patent No. 6,417,335, , U.S. Patent No. 9,249,218, U.S. Patent No. 8,574,869, U.S. Patent No.
`
`6,620,918, U.S. Patent No. 7,993,834, U.S. Patent No. 8,076,066, U.S. Patent No. 8,425,908, U.S.
`
`Patent No. 8,440,402, U.S. Patent No. 6,121,428, U.S. Patent No. 8,512,983, and U.S. Patent No.
`
`9,714,293. Amgen denies the remaining allegations of paragraph 42, and denies the merits of
`
`Genentech’s allegations of infringement.
`
`- 7 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 9 of 1559
`PageID #: 35156
`
`The Cabilly Patents
`
`43.
`
`Amgen admits that U.S. Patent Nos. 6,331,415 and 7,923,221 purport to relate to a
`
`process for producing monoclonal antibodies from recombinant DNA. Amgen lacks sufficient
`
`knowledge or information to form a belief as to the truth of the remaining allegations of paragraph
`
`43, and on that basis denies them.
`
`44.
`
`Amgen admits that U.S. Patent No. 6,331,415 (“the ’415 patent”) is titled “Methods
`
`of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein.” Amgen
`
`further admits that the face of the ’415 patent reflects (1) an issue date of December 18, 2001 and
`
`(2) that the patent was assigned to Genentech and City of Hope. Amgen admits that Exhibit A to
`
`the Complaint purports to be a copy of the ’415 patent. Amgen denies that the ’415 patent was
`
`“duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to
`
`the truth of the remaining allegations of paragraph 44, and on that basis denies them.
`
`45.
`
`Amgen admits that U.S. Patent No. 7,923,221 (“the ’221 patent”) is titled “Methods
`
`of Making Antibody Heavy and Light Chains Having Specificity for a Desired Antigen.” Amgen
`
`further admits that the face of the ’221 patent reflects (1) an issue date of April 12, 2011 and (2)
`
`that the patent was assigned to Genentech and City of Hope. Amgen admits that Exhibit B to the
`
`Complaint purports to be a copy of the ’221 patent. Amgen denies that the ’221 patent was “duly
`
`and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to the
`
`truth of the remaining allegations of paragraph 45, and on that basis denies them.
`
`The ’213 Patent
`
`46.
`
`Amgen admits that U.S. Patent No. 6,407,213 (“the ’213 patent”) purports to relate
`
`to a humanized antibody and/or a humanized antibody variable domain. Amgen lacks sufficient
`
`knowledge or information to form a belief as to the truth of the remaining allegations of paragraph
`
`46, and on that basis denies them.
`
`- 8 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 10 of 1559
`PageID #: 35157
`
`47.
`
`Amgen admits that the ’213 patent is titled “Methods of Making Humanized
`
`Antibodies.” Amgen further admits that the face of the ’213 patent reflects (1) an issue date of
`
`June 18, 2002 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit C to
`
`the Complaint purports to be a copy of the ’213 patent. Amgen denies that the ’213 patent was
`
`“duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to
`
`the truth of the remaining allegations of paragraph 47, and on that basis denies them.
`
`The Combination Chemotherapy Patents
`
`48.
`
`Amgen admits that U.S. Patent No. 7,846,441 (“the ’441 patent”) purports to relate
`
`to a method of administering anti-ErbB2 antibodies. Amgen lacks sufficient knowledge or
`
`information to form a belief as to the truth of the remaining allegations of paragraph 48, and on
`
`that basis denies them.
`
`49.
`
`Amgen admits that the ’441 patent is titled “Treatment with Anti-ErbB2
`
`Antibodies.” Amgen further admits that the face of the ’441 patent reflects (1) an issue date of
`
`December 7, 2010 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit
`
`D to the Complaint purports to be a copy of the ’441 patent. Amgen denies that the ’441 patent
`
`was “duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief
`
`as to the truth of the remaining allegations of paragraph 49, and on that basis denies them.
`
`50.
`
`Amgen admits that U.S. Patent No. 7,892,549 (“the ’549 patent”) purports to be a
`
`continuation of the ’441 patent, and purports to relate to a method of treating a patient with HER2-
`
`positive breast cancer using anti-ErbB2 antibodies. Amgen lacks sufficient knowledge or
`
`information to form a belief as to the truth of the remaining allegations of paragraph 50, and on
`
`that basis denies them.
`
`51.
`
`Amgen admits that the ’549 patent is titled “Treatment with Anti-ErbB2
`
`Antibodies.” Amgen further admits that the face of the ’549 patent reflects (1) an issue date of
`
`- 9 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 11 of 1559
`PageID #: 35158
`
`February 22, 2011 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit
`
`E to the Complaint purports to be a copy of the ’549 patent. Amgen denies that the ’549 patent
`
`was “duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief
`
`as to the truth of the remaining allegations of paragraph 51, and on that basis denies them.
`
`52.
`
`Amgen admits that U.S. Patent No. 8,425,908 (“the ’908 patent”) purports to claim
`
`priority to the same provisional application as the’441 and ’549 patents. Amgen admits that the
`
`’908 patent purports to relate to a method of treating a patient with HER2-positive gastric cancer
`
`using anti-ErbB2 antibodies. Amgen lacks sufficient knowledge or information to form a belief
`
`as to the truth of the remaining allegations of paragraph 52, and on that basis denies them.
`
`53.
`
`Amgen admits that the ’908 patent is titled “Treatment with Anti-ErbB2
`
`Antibodies.” Amgen further admits that the face of the ’908 patent reflects (1) an issue date of
`
`April 23, 2013 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit F to
`
`the Complaint purports to be a copy of the ’908 patent. Amgen denies that the ’908 patent was
`
`“duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to
`
`the truth of the remaining allegations of paragraph 53, and on that basis denies them.
`
`The Method of Administration Patents
`
`54.
`
`Amgen admits that U.S. Patent Nos. 6,627,196 and 7,371,379 purport to relate to a
`
`method of administering anti-ErbB2 antibodies. Amgen lacks sufficient knowledge or information
`
`to form a belief as to the truth of the remaining allegations of paragraph 54, and on that basis denies
`
`them.
`
`55.
`
`Amgen admits that U.S. Patent No. 6,627,196 (“the ’196 patent”) is titled “Dosages
`
`for Treatment with Anti-ErbB2 Antibodies.” Amgen further admits that the face of the’196 patent
`
`reflects (1) an issue date of September 30, 2003 and (2) that the patent was assigned to Genentech.
`
`Amgen admits that Exhibit G to the Complaint purports to be a copy of the’196 patent. Amgen
`
`- 10 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 12 of 1559
`PageID #: 35159
`
`denies that the ’196 patent was “duly and legally” issued. Amgen lacks sufficient knowledge or
`
`information to form a belief as to the truth of the remaining allegations of paragraph 55, and on
`
`that basis denies them.
`
`56.
`
`Amgen admits that U.S. Patent No. 7,371,379 (“the ’379 patent”) is titled “Dosages
`
`for Treatment with Anti-ErbB2 Antibodies.” Amgen further admits that the face of the ’379 patent
`
`reflects (1) an issue date of May 13, 2008 and (2) that the patent was assigned to Genentech.
`
`Amgen admits that Exhibit H to the Complaint purports to be a copy of the ’379 patent. Amgen
`
`denies that the ’379 patent was “duly and legally” issued. Amgen lacks sufficient knowledge or
`
`information to form a belief as to the truth of the remaining allegations of paragraph 56, and on
`
`that basis denies them.
`
`The Acidic Variants Patents
`
`57.
`
`Amgen admits that U.S. Patent Nos. 6,417,335 and 9,249,218 purport to relate to a
`
`method for purifying a polypeptide by ion exchange chromatography. Amgen lacks sufficient
`
`knowledge or information to form a belief as to the truth of the remaining allegations of paragraph
`
`57, and on that basis denies them.
`
`58.
`
`Amgen admits that U.S. Patent No. 6,417,335 (“the ’335 patent”) is titled “Protein
`
`Purification.” Amgen further admits that the face of the ’335 patent indicates (1) an issue date of
`
`July 9, 2002 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit I to
`
`the Complaint purports to be a copy of the ’335 patent. Amgen denies that the ’335 patent was
`
`“duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to
`
`the truth of the remaining allegations of paragraph 58, and on that basis denies them.
`
`59.
`
`Amgen admits that U.S. Patent No. 9,249,218 (“the ’218 patent”) is titled “Protein
`
`Purification.” Amgen further admits that the face of the ’218 patent indicates (1) an issue date of
`
`February 2, 2016 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit J
`
`- 11 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 13 of 1559
`PageID #: 35160
`
`to the Complaint purports to be a copy of the ’218 patent. Amgen denies that the ’218 patent was
`
`“duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to
`
`the truth of the remaining allegations of paragraph 59, and on that basis denies them.
`
`HER2 Diagnostic Patents
`
`60.
`
`Amgen admits that U.S. Patent Nos. 7,993,834, 8,076,066, and 8,440,402 purport
`
`to relate to techniques for identifying patients who might benefit from ErbB2 antibody therapy
`
`using gene amplification. Amgen lacks sufficient knowledge or information to form a belief as to
`
`the truth of the remaining allegations of paragraph 60, and on that basis denies them.
`
`61.
`
`Amgen admits that U.S. Patent No. 7,993,834 (“the ’834 patent”) is titled
`
`“Detection of ErbB2 Gene Amplification to Increase the Likelihood of the Effectiveness of ErbB2
`
`Antibody Breast Cancer Therapy.” Amgen further admits that the face of the ’834 patent indicates
`
`(1) an issue date of August 9, 2011 and (2) that the patent was assigned to Genentech. Amgen
`
`admits that Exhibit K to the Complaint purports to be a copy of the ’834 patent. Amgen denies
`
`that the ’834 patent was “duly and legally” issued. Amgen lacks sufficient knowledge or
`
`information to form a belief as to the truth of the remaining allegations of paragraph 61, and on
`
`that basis denies them.
`
`62.
`
`Amgen admits that U.S. Patent No. 8,076,066 (“the ’066 patent”) is titled “Gene
`
`Detection Assay for Improving the Likelihood of an Effective Response to a HER2 Antibody
`
`Cancer Therapy.” Amgen further admits that the face of the ’066 patent indicates (1) an issue date
`
`of December 13, 2011 and (2) that the patent was assigned to Genentech. Amgen admits that
`
`Exhibit L to the Complaint purports to be a copy of the ’066 patent. Amgen denies that the ’066
`
`patent was “duly and legally” issued. Amgen lacks sufficient knowledge or information to form a
`
`belief as to the truth of the remaining allegations of paragraph 62, and on that basis denies them.
`
`- 12 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 14 of 1559
`PageID #: 35161
`
`63.
`
`Amgen admits that U.S. Patent No. 8,440,402 (“the ’402 patent”) is titled “Gene
`
`Detection Assay for Improving the Likelihood of an Effective Response to a HER2 Antibody
`
`Cancer Therapy.” Amgen further admits that the face of the ’402 patent indicates (1) an issue date
`
`of May 14, 2013 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit
`
`M to the Complaint purports to be a copy of the ’402 patent. Amgen denies that the ’402 patent
`
`was “duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief
`
`as to the truth of the remaining allegations of paragraph 63, and on that basis denies them.
`
`Cell Culture, Purification, and Antibody Manufacturing Patents
`
`64.
`
`Amgen admits that U.S. Patent Nos. 6,121,428, 6,620,918, 8,512,983, 8,574,869,
`
`and 9,714,293 purport to relate to various subject matter including cell culture, purification, and
`
`antibody purification. Amgen lacks sufficient knowledge or information to form a belief as to the
`
`truth of the remaining allegations of paragraph 64, and on that basis denies them.
`
`65.
`
`Amgen admits that U.S. Patent No. 6,121,428 (“the ’428 patent”) is titled “Protein
`
`Recovery.” Amgen further admits that the face of the ’428 patent indicates (1) an issue date of
`
`September 19, 2000 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit
`
`N to the Complaint purports to be a copy of the ’428 patent. Amgen denies that the ’428 patent
`
`was “duly and legally” issued. Amgen lacks sufficient knowledge or information to form a belief
`
`as to the truth of the remaining allegations of paragraph 65, and on that basis denies them.
`
`66.
`
`Amgen admits that U.S. Patent No. 6,620,918 (“the ’918 patent”) is titled
`
`“Separation of Polypeptide Monomers.” Amgen further admits that the face of the ’918 patent
`
`indicates (1) an issue date of September 16, 2003 and (2) that the patent was assigned to Genentech.
`
`Amgen admits that Exhibit O to the Complaint purports to be a copy of the ’918 patent. Amgen
`
`denies that the ’918 patent was “duly and legally” issued. Amgen lacks sufficient knowledge or
`
`- 13 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 15 of 1559
`PageID #: 35162
`
`information to form a belief as to the truth of the remaining allegations of paragraph 66, and on
`
`that basis denies them.
`
`67.
`
`Amgen admits that U.S. Patent No. 8,512,983 (“the ’983 patent”) is titled
`
`“Production of Proteins in Glutamine-Free Cell Culture Media.” Amgen further admits that the
`
`face of the ’983 patent indicates (1) an issue date of August 20, 2013 and (2) that the patent was
`
`assigned to Genentech. Amgen admits that Exhibit P to the Complaint purports to be a copy of
`
`the ’983 patent. Amgen denies that the ’983 patent was “duly and legally” issued. Amgen lacks
`
`sufficient knowledge or information to form a belief as to the truth of the remaining allegations of
`
`paragraph 67, and on that basis denies them.
`
`68.
`
`Amgen admits that U.S. Patent No. 8,574,869 (“the ’869 patent”) is titled
`
`“Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides.”
`
`Amgen further admits that the face of the ’869 patent indicates (1) an issue date of November 5,
`
`2013 and (2) that the patent was assigned to Genentech. Amgen admits that Exhibit Q to the
`
`Complaint purports to be a copy of the ’869 patent. Amgen denies that the ’869 patent was “duly
`
`and legally” issued. Amgen lacks sufficient knowledge or information to form a belief as to the
`
`truth of the remaining allegations of paragraph 68, and on that basis denies them.
`
`69.
`
`Amgen admits that U.S. Patent No. 9,714,293 (“the ’293 patent”) is titled
`
`“Production of Proteins in Glutamine-Free Cell Culture Media.” Amgen further admits that the
`
`face of the ’293 patent indicates (1) an issue date of July 25, 2017 and (2) that the patent was
`
`assigned to Genentech. Amgen admits that Exhibit R to the Complaint purports to be a copy of
`
`the ’293 patent. Amgen denies that the ’293 patent was “duly and legally” issued. Amgen lacks
`
`sufficient knowledge or information to form a belief as to the truth of the remaining allegations of
`
`paragraph 69, and on that basis denies them.
`
`- 14 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 16 of 1559
`PageID #: 35163
`
`COUNT I
`INFRINGEMENT OF U.S. PATENT NO. 6,331,415
`
`70.
`
`Amgen incorporates each of its responses to the preceding paragraphs as if fully set
`
`forth herein.
`
`71.
`
`Amgen admits that Genentech included the ’415 patent in its 3A and 3C Statements.
`
`Amgen denies the remaining allegations in paragraph 71.
`
`72.
`
`Amgen admits that it submitted its BLA to the FDA on July 28, 2017. Amgen
`
`denies the remaining allegations of paragraph 72.
`
`73.
`
`Amgen admits that it notified Genentech pursuant to 42 U.S.C. § 262(l)(8)(A) that
`
`it intends to commence first commercial marketing of ABP 980 in the United States no earlier than
`
`180 days from May 15, 2018 (i.e., November 11, 2018). Amgen denies the remaining allegations
`
`in paragraph 73.
`
`74.
`
`75.
`
`Amgen denies the allegations of paragraph 74.
`
`Amgen admits that Genentech included the ’415 patent on its 3A and 3C
`
`Statements. Amgen denies the remaining allegations of paragraph 75.
`
`76.
`
`77.
`
`Amgen denies the allegations of paragraph 76.
`
`Amgen denies the allegations of paragraph 77.
`
`COUNT II
`INFRINGEMENT OF U.S. PATENT NO. 7,923,221
`
`78.
`
`Amgen incorporates each of its responses to the preceding paragraphs as if fully set
`
`forth herein.
`
`79.
`
`Amgen admits that Genentech included the ’221 patent in its 3A and 3C Statements.
`
`Amgen denies the remaining allegations in paragraph 79.
`
`80.
`
`Amgen admits that it submitted its BLA to the FDA on July 28, 2017. Amgen
`
`denies the remaining allegations of paragraph 80.
`
`- 15 –
`CONFIDENTIAL – FILED UNDER SEAL PURSUANT TO LOCAL RULE 26.2
`
`

`

`Case 1:18-cv-00924-CFC-SRF Document 563-2 Filed 11/09/20 Page 17 of 1559
`PageID #: 35164
`
`81.
`
`Amgen admits that it notified Genentech pursuant to 42 U.S.C. § 262(l)(8)(A) that
`
`it intends to commence first commercial marketing of ABP 980 in the United States no earlier than
`
`180 days from May 15, 2018 (i.e., November 11, 2018). Amgen denies the remaining allegations
`
`in paragraph 81.
`
`82.
`
`83.
`
`Amgen denies the allegations of paragraph 82.
`
`Amgen admits that Genentech included the ’221 patent on its 3A and 3C
`
`Statements. Amgen denies the remaining allegations of paragraph 83.
`
`84.
`
`85.
`
`Amgen denies the allegations of paragraph 84.
`
`Amgen denies the allegations of paragraph 85.
`
`COUNT III
`INFRINGEMENT OF U.S. PATENT NO. 6,407,213
`
`86.
`
`Amgen incorporates each of its responses to the preceding paragraphs as if fully set
`
`forth herein.
`
`87.
`
`Amgen admits that Genentech included the ’213 patent in its 3A and 3C Statements.
`
`Amgen denies the remaining allegations in paragraph 87.
`
`88.
`
`Amgen admits that it submitted its BLA to the FDA on July 28, 2017. Amgen
`
`denies the remaining allegations of paragraph 88.
`
`89.
`
`Amgen admits that it notified Genentech pursuant to 42 U.S.C. § 262(l)(8)(A) that
`
`it intends to commence first commercial marketing of ABP 980 in the United States no earlier than
`
`180 days from May 15, 2018 (i.e., November 11, 2018). Amgen denies the remaining allegations
`
`in paragraph 89.
`
`90.
`
`91.
`
`Amgen denies the allegations of paragraph 90.
`
`Amgen admits that Genentech included the ’213 patent on its 3A and 3C
`
`Stateme